MarketVIEW STD Vaccines  ·  January 2024 edition

Gonococcal Vaccines
Forecast

Gonorrhoea infects 82 million people a year and has become one of the WHO's critical antimicrobial resistance threats, yet 2026's landmark trial data delivered an unwelcome reversal: rigorous randomised trials confirmed that GSK's Bexsero meningococcal B vaccine, gonorrhoea's one repurposed near-term hope, does not protect against the disease after all. This is a comprehensive, wide geography commercial assessment of the gonococcal vaccine opportunity that draws a clear line between that failed programme and GSK's separate, purpose-built NgG candidate, whose own readout remains pending, drawing on VacZine Analytics' long standing, independent authority in STD vaccine markets.

82 Million New Infections a Year Bexsero/MenB Cross-Protection Fails 10 High-Income Nations Modelled GSK's NgG: Readout Still Pending
Product catalogue
VAMV091
January 2024 edition

Format
PDF (>225 slides) + Excel (120 sheets)
Coverage
10 high-income nations
Vaccines assessed
Ng-specific & MenB candidates
Forecast horizon
Scenario-based, multi-year
Approach
Public/private uptake modelling
Base edition
January 2024
Availability
Syndicated / bespoke
82M
New Neisseria gonorrhoeae
infections a year (ages 15 to 49)
2nd
Most common bacterial
sexually transmitted infection
-0.5%
GoGoVax trial efficacy of Bexsero
against gonorrhoea in high-risk MSM
6x
Rise in ceftriaxone/azithromycin
resistance, WHO EGASP, 2022 to 2024
Disease background

A high-volume STI with a resistance problem, and a 2026 evidence reversal

This review sets out the current disease background, global burden and resistance trends for Neisseria gonorrhoeae before examining a competitor landscape that shifted meaningfully in 2026.

WHO EGASP 2024 data & 2026 trial results

Pathogen overview - Neisseria gonorrhoeae (Ng)

Neisseria gonorrhoeae (Ng) is a Gram-negative bacterium responsible for gonorrhoea, the second most common bacterial sexually transmitted infection worldwide, causing an estimated 82 million new infections a year among 15 to 49 year olds. Infection is frequently asymptomatic, but in women, ascending Ng infection can cause pelvic inflammatory disease, ectopic pregnancy and infertility. Ng infection also elevates the risk of HIV acquisition and transmission, and can cause neonatal conjunctivitis severe enough to result in blindness.

Although generally treatable with antibiotics, Ng has a remarkable capacity to acquire resistance against successive antibiotic classes, and the WHO considers this a critical AMR threat. The WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) continues to document rising resistance to ceftriaxone and azithromycin, the two primary first-line treatments; WHO surveillance data published in late 2025 showed resistance to those two agents rose more than sixfold between 2022 and 2024, and ceftriaxone is now the only one of the two still recommended by the CDC. Essentially all detected infections already carry resistance to at least one of penicillin, tetracycline or ciprofloxacin, historic first-line agents. New treatment options are arriving to relieve some of that pressure: the FDA approved two new antibiotics for gonorrhoea in December, Blujepa (gepotidacin, GSK) and Nuzolvence (zoliflodacin, Innoviva Specialty Therapeutics), the first new drug classes for the infection in more than four decades. But new antibiotics treat individual infections; they do not remove the case for prevention. A prophylactic Ng-specific vaccine could reduce adverse reproductive health outcomes and directly relieve pressure on the antibiotic arsenal at a population level, and could be targeted routinely to adolescents and young adults or to higher-risk groups such as gay, bisexual and other men who have sex with men (GBMSM), who account for a disproportionate share of diagnoses.

2026 delivered a major reversal for the field's leading near-term hypothesis, and it is important to be precise about which GSK programme it affected. Meningococcal serogroup B (MenB) vaccines, notably GSK's Bexsero (4CMenB), a vaccine originally developed against meningococcal disease and only ever a repurposed candidate for gonorrhoea, had shown promising cross-protective signals in observational studies, with meta-analyses of eight such studies estimating pooled effectiveness of 30% to 35%. That evidence prompted the UK Health Security Agency to approve Bexsero for gonorrhoea prevention in high-risk populations in August 2025 and to launch the world's first gonorrhoea vaccination programme in sexual health clinics. It has not held up under randomised testing. A French trial reported at CROI 2024 already found no protective effect, reversing its own encouraging interim data from a year earlier, and Griffith University's GoGoVax study, presented at CROI in February 2026 among 587 high-risk MSM in Australia, confirmed it decisively: gonorrhoea incidence was 48.1 cases per 100 person-years on Bexsero versus 47.8 on placebo, a vaccine efficacy of -0.5% (95% CI, -26.2 to 19.9). Griffith's Kate Seib, presenting the result, held out hope the vaccine could still work in other populations, but co-panellist Jean-Michel Molina was blunter, arguing mucosal protection looks unlikely and that the field needs a better-designed vaccine. The UKHSA policy decision now sits ahead of the definitive trial evidence, a genuine live issue for market access and positioning discussions this report addresses directly. Crucially, this failure sits entirely outside GSK's other, purpose-built gonococcal programme: NgG (GSK4348413), a pathogen-specific GMMA-based candidate, is a separate vaccine on a separate development track, and its own Phase I/II proof-of-concept readout, originally expected in 2025, has not been publicly reported as of August 2026.

2026 82M new infections/year  |  resistance to first-line antibiotics up 6x, 2022 to 2024  |  Bexsero/MenB cross-protection decisively disproven in RCTs  |  GSK's separate, pathogen-specific NgG candidate still awaiting its overdue readout
Product & competitor landscape

GSK's two gonorrhoea vaccine programmes have both now reported disappointing results

2026 delivered readouts for both of GSK's gonorrhoea vaccine approaches: Bexsero's MenB cross-protection was decisively disproven in randomised trials, and GSK's own GMMA-based NgG candidate has now also reported, missing its primary Phase II efficacy endpoint.

  • GSKPhase II readout: primary endpoint not met
    NgG (GSK4348413) GMMA-based, pathogen-specific
    The field's most advanced pathogen-specific candidate, and a distinct programme from Bexsero. Its Phase I/II trial (NCT05630859), around 1,000 healthy adults across multiple countries, completed its Phase I safety lead-in and moved into a Phase II proof-of-concept stage from November 2022. Results posted to ClinicalTrials.gov on 16 June 2026 show vaccine efficacy against confirmed gonorrhoea of 9.9% (higher dose) and 10.9% (lower dose) versus placebo, with 85% confidence intervals spanning zero for both doses; the primary efficacy hypothesis was not met, though the safety profile was clean (no serious adverse events reported in the Phase I lead-in). The vaccine retains its US FDA Fast Track designation; GSK has not yet issued a public statement on the programme's next steps.
  • GSK / academiaDecisively disproven across two RCTs
    Bexsero (4CMenB) cross-protection
    A French trial reported at CROI 2024 and Griffith University's GoGoVax trial, reported at CROI in February 2026 (587 high-risk MSM in Australia, efficacy -0.5%), both found no protective effect against gonorrhoea, reversing earlier 30% to 35% observational effectiveness estimates and creating a policy/evidence gap given UKHSA's August 2025 approval for high-risk use. In an FAQ update first published 29 May 2026 and revised 31 July 2026, UKHSA confirmed England's 4CMenB gonorrhoea programme continues regardless, citing the ongoing need to cut incidence, ongoing observational and modelling support (including South Australian adolescent data estimating 46% effectiveness over four years), and reporting over 35,000 first doses given with 40% uptake among eligible GBMSM by December 2025; the JCVI will formally review real-world UK programme effectiveness data, with findings expected later in 2026 to 2027, before deciding the programme's future. Separately, a JCVI statement dated 16 July 2026, prompted by a MenB disease outbreak in Kent rather than by gonorrhoea policy, recommended a routine adolescent 4CMenB dose at around age 15 for those primed in infancy (from 2030), plus two-dose catch-up offers for unprimed and intermediate cohorts; the statement cited observational gonococcal cross-protection evidence, including South Australian two-dose effectiveness of 41.8% against gonorrhoea (waning out to five years), as supporting context, meaning routine adolescent 4CMenB dosing, if implemented following the still-pending DHSC decision, could extend gonorrhoea-relevant MenB coverage well beyond the current targeted GBMSM programme. This is a repurposed meningococcal B vaccine, not a purpose-built gonococcal candidate, and its failure has no bearing on GSK's separate NgG programme above.
  • Jenner Institute / Intravacc / EvaxionEarly clinical & preclinical
    Gonovac, Avacc-11, EVX-B2
    A broader field of earlier-stage pathogen-specific candidates spanning academic and biotech developers, providing pipeline depth behind GSK's lead programme.
  • LimmaTech Biologics (acquired by Eli Lilly, May 2026)Phase I: recruiting from Aug 2026
    LTB-NG6 Multivalent, six-antigen candidate
    LimmaTech's hexavalent gonococcal candidate has moved from preclinical development into a Phase I safety and immunogenicity trial (NCT07758972) in healthy adults, posted to ClinicalTrials.gov on 11 August 2026 and recruiting at a German site, with primary completion estimated for April 2027. LimmaTech was acquired by Eli Lilly for up to $780m in a May 2026 deal covering its bacterial vaccine pipeline, including this gonorrhoea programme.
  • GSK / Innoviva Specialty TherapeuticsComplementary, not preventive
    Novel antibiotics: Blujepa (gepotidacin) & Nuzolvence (zoliflodacin)
    FDA-approved in December, the first new antibiotic classes against gonorrhoea in more than four decades. They treat individual drug-resistant infections rather than prevent transmission, reinforcing rather than replacing the case for a vaccine.
Field reset
2026

2026 brought definitive, disappointing randomised trial data for both of GSK's gonorrhoea vaccine approaches. Bexsero/MenB cross-protection was decisively disproven, reversing years of encouraging observational signal and leaving a policy decision, UKHSA's August 2025 approval, stranded ahead of the evidence. GSK's purpose-built, pathogen-specific NgG candidate has now reported too: results posted to ClinicalTrials.gov on 16 June 2026 show neither dose met its primary Phase II efficacy endpoint (9.9% to 10.9% efficacy, confidence intervals spanning zero), even though the safety profile was clean. The VacZine Analytics model treats these as two distinct, independently-risked programmes and quantifies the commercial opportunity across both under multiple pipeline-progression scenarios, now updated for both 2026 readouts.

Scope of analysis

Six analytical layers - one commercial picture

This is a genuinely comprehensive report with a wide geographic focus, spanning disease burden, resistance trends, the R&D competitive landscape and scenario-based uptake forecasting across 10 high-income nations.

Uptake forecast across 10 nations

Scenario-based public/private uptake modelling of Ng-specific and MenB vaccines across key target groups in 10 high-income nations.

Competitor & pipeline review

Full review of GSK's separate NgG and Bexsero programmes, the disproven MenB cross-protection hypothesis, and the wider pathogen-specific pipeline.

Target product profile & pricing

In-depth commercial assessment of vaccine profiles, target population rationale, potential pricing and clinical development feasibility.

Scenario-based revenue forecasts

Volume and value forecasts reflecting the shift toward pathogen-specific candidates following 2026's MenB trial results.

Disease burden & resistance trends

Global burden and WHO EGASP antimicrobial resistance data, including the 2024 reference strain update.

Meningococcal B cross-protection review

Dedicated commercial investigation into monovalent and pentavalent MenB vaccines' cross-protective capacity, updated for the 2026 RCT results and UKHSA policy context.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the target-population and geography framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.

Target populationGeographyVaccine approachSettingRevenue scenario
Adolescents / young adults10 high-income nationsNg-specific (NgG)Routine/targetedModelled
GBMSM, higher-risk groups10 high-income nationsNg-specific (NgG)Targeted, public/privateModelled
GBMSM, higher-risk groups10 high-income nationsMenB (pentavalent)Targeted, policy-dependentModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - base10-nation modelAll approachesAll settings$███m
Full model in the licensed workbook
10 high-income nations · public/private · Ng-specific & MenB approaches
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations evaluating the gonococcal vaccine opportunity across major developed markets.

  • Executive presentation (>225 slides, PDF) - disease background, epidemiology, resistance trends, competitor pipeline and full commercial assessment with supporting narrative and references
  • Interactive MS-Excel forecast workbook (120 worksheets) - scenario-based uptake and value/volume outputs across 10 high-income nations
  • Meningococcal B cross-protection assessment - dedicated commercial investigation into Bexsero and pentavalent MenB vaccines, updated for the CROI 2024/2026 RCT results and UKHSA policy
  • Competitor intelligence - GSK's separate NgG (GSK4348413) and Bexsero programmes, Gonovac, Avacc-11, EVX-B2 and Limmatech's hexavalent approach
  • Updated epidemiology & resistance module - WHO EGASP data and the sixfold 2022-2024 rise in ceftriaxone/azithromycin resistance
  • Target population, pricing & feasibility review - target product profile rationale, potential uptake, pricing and clinical development issues
Target audience

Built for organisations weighing the gonococcal vaccine opportunity

Most valuable to teams evaluating the gonococcal vaccine market against their own pipeline, BD ambitions or investment thesis, particularly following 2026's decisive MenB trial results.

Vaccine developers

Positioning and commercial feasibility assessment for Ng-specific candidates at any stage, informed by GSK's lead programme.

Corporate strategy & BD

Validate the size and structure of the market following 2026's MenB cross-protection reversal and GSK's continued lead.

Investors & analysts

Independent assessment of pipeline risk for due diligence on GSK's NgG and adjacent STD/AMR vaccine assets.

Public health & sexual health programmes

Demand modelling and policy review to support future gonorrhoea prevention programme planning, including MenB positioning questions.

Researchers & academia

Comprehensive epidemiology, resistance and R&D landscape for grant and translational planning.

Market access & policy

Pricing benchmarks and access-pathway assumptions, including the UKHSA MenB policy precedent, across 10 high-income nations.

About this analysis · VAMV091

VacZine Analytics has tracked STD vaccine markets since our earliest editions, positioning us to reassess the gonococcal vaccine opportunity the moment 2026's MenB trial results reshaped the field, and to draw a clear line between the GSK programme that failed and the separate one that has not yet reported. This is a genuinely comprehensive analysis with a wide geographic focus across 10 high-income nations, and it has been well received by clients across the field for the depth of its resistance-trend and target product profile review. Few groups have followed this market as closely, and that recognised, independent expertise underpins everything in the analysis.

This report was last published in January 2024; any refresh would incorporate current WHO EGASP resistance data, the decisive CROI 2026 randomised trial results on Bexsero/meningococcal B cross-protection, and the continued, still-pending status of GSK's separate, purpose-built NgG candidate. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV091 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc gonococcal vaccine analysis, a briefing call is included on request.